Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). (Q48640874)

13 February 2018

title

Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). (English)

1 reference

13 February 2018

0 references

1 reference

ChEBI release 2020-05-28

5

1 reference

13 February 2018

Piotr Ponikowski

Piotr Ponikowski

6

0 references

Mihai Gheorghiade

14

Mihai Gheorghiade

1 reference

13 February 2018

2

Javed Butler

1 reference

13 February 2018

3

Gerasimos Filippatos

1 reference

13 February 2018

1

Burkert Pieske

1 reference

13 February 2018

4

Carolyn Lam

1 reference

13 February 2018

Sanjiv J Shah

7

Sanjiv Shah

1 reference

13 February 2018

Lothar Roessig

13

Lothar Roessig

1 reference

13 February 2018

Andrea-Viviana Scalise

11

Andrea Viviana Scalise

1 reference

13 February 2018

Elisabeth Kraigher-Krainer

9

Elisabeth Kraigher-Krainer

1 reference

13 February 2018

author name string

Scott Solomon

8

1 reference

13 February 2018

Eliana Tibana Samano

10

1 reference

13 February 2018

Katharina Müller

12

1 reference

13 February 2018

SOCRATES Investigators and Coordinators

15

1 reference

13 February 2018

publication date

24 July 2014

1 reference

13 February 2018

European Journal of Heart Failure

published in

1 reference

13 February 2018

volume

16

1 reference

13 February 2018

issue

9

1 reference

13 February 2018

page(s)

1026-1038

1 reference

13 February 2018

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

cites work

1 reference

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).

21 January 2018

1 reference

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial

21 January 2018

1 reference

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

21 January 2018

1 reference

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

21 January 2018

1 reference

Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity

21 January 2018

1 reference

Soluble guanylate cyclase: a potential therapeutic target for heart failure

21 January 2018

1 reference

Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice

21 January 2018

1 reference

sGC{alpha}1 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handling

21 January 2018

1 reference

Low myocardial protein kinase G activity in heart failure with preserved ejection fraction.

21 January 2018

1 reference

Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics

21 January 2018

1 reference

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

21 January 2018

1 reference

The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction

21 January 2018

1 reference

Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease

21 January 2018

1 reference

Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group

21 January 2018

1 reference

Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial

21 January 2018

1 reference

Explaining the phenomenon of nitrate tolerance

21 January 2018

1 reference

Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression.

21 January 2018

1 reference

Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions

21 January 2018

1 reference

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial

21 January 2018

1 reference

Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure

21 January 2018

1 reference

Riociguat for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension

21 January 2018

1 reference

Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.

21 January 2018

1 reference

Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research

21 January 2018

1 reference

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

21 January 2018

1 reference

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

21 January 2018

1 reference

Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study.

21 January 2018

1 reference

B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction

21 January 2018

1 reference

Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study.

21 January 2018

1 reference

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology

21 January 2018

1 reference

Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis.

21 January 2018

1 reference

Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath

21 January 2018

1 reference

Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT.

21 January 2018

1 reference

Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research.

21 January 2018

1 reference

Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management

21 January 2018

1 reference

Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.

21 January 2018

1 reference

Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction

21 January 2018

1 reference

Left atrial volume and the benefit of cardiac resynchronization therapy in the MADIT-CRT trial

21 January 2018

1 reference

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

21 January 2018

1 reference

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial

21 January 2018

1 reference

Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes

21 January 2018

1 reference

Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction

21 January 2018

1 reference

Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Why do drugs for acute heart failure fail?

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/EJHF.135

1 reference

13 February 2018

PubMed ID

25056511

1 reference

13 February 2018